3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Conditions
Recurrence
2
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Interventions
pembrolizumab
30
Cisplatin
20
Carboplatin
20
Paclitaxel
18
Dexamethasone
15
Pemetrexed
13
Nivolumab
13
Ipilimumab
12
Fluorouracil
11
Cyclophosphamide
11
Gemcitabine
10
Trastuzumab
9
Docetaxel
9
Cytarabine
9
daratumumab
8
atezolizumab
8
Rituximab
8
Capecitabine
8
Lenalidomide
7
Doxorubicin
7
zanubrutinib
6
Prednisone
6
Daunorubicin
6
Bortezomib
6
venetoclax
5
trametinib
5
nilotinib
5
ibrutinib
5
fludarabine
5
dabrafenib
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
Has announcements
×
tisagenlecleucel
×
Clear all
NCT03568461
2025-10-07
ELARA
Novartis
Phase 2
Completed
98 enrolled
9 charts
1 FDA
NCT02445248
2024-04-18
JULIET
Novartis
Phase 2
Completed
115 enrolled
22 charts
1 FDA